Thesis. Invalidation. Catalyst. Per ticker.

The 2026-08-04 bounce failed: ARCB lost the $136 shelf on a 2026-08-06 close of $135.25 and printed a post-print low of $134.75 on 08-07, while three open-market director sales — the first of 2026 — executed at $138.71–$144.85 on 08-04 and…

Q1 FY27 (2026-07-29) beat, but Q2 royalty growth was guided to ~13% from the 22% delivered, on memory-driven handset weakness. The 2026-08-04 +17.36% snapback to $280.56 lifted price above six of nine published post-print targets and to…

The 2026-08-04 spectrum re-rating gap has largely round-tripped: $106.35 close, then $99.41, $100.32 and $99.26 through 2026-08-07, heaviest volume on the down day. The 1.0M-share dilution vote passed on 2026-08-04; the 2026-08-11 Q1…

Post-print recovery extended: $65.77 close on 2026-08-07 (+2.45%), above the 20-day and 50-day levels marked on 08-04, with the $69.36 52-week high in view. Two dated events inside four sessions — CMS's 3:00pm EDT 2026-08-12 PY2027 rate…

Beat-and-raise sold hard: $430.16 on 08-05 to $317.93 on 08-07, -26.1% in two sessions on the window's heaviest volume, while four brokers raised targets to $449–$490 on 08-06. Growth intact (FY26 guide up to $725–735M, adj EPS…

AI-server order book unchanged since the 2026-05-28 print ($51.3B backlog, ~$60B FY27 AI-server guide) while price added 26.4% in four sessions to a $467.27 close on 2026-08-04 — a new high built on cohort beta and Micron-driven sentiment,…

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating…

Deal-arb discount narrowed to 7.5%: RKLB closed $82.83 on 2026-08-07, $15.33 inside the collar's flat band, so the package still marks $54.00 against IRDM's $49.93. Forty days post-announcement there is still no Form S-4, no FCC docket and…

Freight-recovery leg unresolved between the $266.91 low of 2026-08-03 and the $276.28 pre-print close; the 2026-08-04 reclaim of the June floor came on 825,678 shares against a 1.11M 20-day average. DAT's 35-day forecast published…

Relief bounce off the broker-liability selloff stalled: LSTR closed $183.09 on 2026-08-07 after $181.62 on 08-04, below the 50-day at $205.13 and above a rising 200-day at $166.56. DAT dry van and flatbed have fallen two straight weeks to…

Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction — chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the…

Record made 2026-08-04 ($190.46 close, $195.70 intraday) has held — 2026-08-07 closed $189.52 with no give-back. Second tuck-in in three weeks (JetStream, 2026-08-06, undisclosed). No Q1 FY27 webcast notice as of 2026-08-09, which argues…

The August 6 binary resolved on the numbers and broke on the tape: EPS $1.10 vs $0.49, guidance raised $250M, stock closed $26.54 from $30.11 and $27.90 on August 7. What is left to buy is a post-print reset into the September 16 Investor…

Q2 printed +51.7% revenue and a third FY26 guidance raise on 2026-08-06, then the stock lost 33.89% to $118.02 on 08-07 as management dated second-half growth at roughly 30%. The acceleration leg is over; what is left is a de-rated…

The 2026-08-04 breakout above the July band failed within three sessions — SNX closed $252.42 on 2026-08-07, back inside the $235.67–$255.70 range and under the 50-day. The move up came on Arista's print, not company news; Hyve's +117%…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

Atera's order book turned the name: the 2026-08-06 beat-and-raise first sold to $45.60, then reversed to a record $52.03 close on 2026-08-07 (+14.10%, 5.43M shares) with the 16-analyst average target moving $41.54→$46.31 in two sessions.…

Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) — late-stage distribution behaviour. The 2026-07-29 Q2…

The 29% bounce off the 2026-07-28 low stalled: WDC closed $527.22 on 2026-08-03, −3.23% on a day its sector rose 0.58%, back under a rising 50-day at $562.65. Consensus (~$3.69B / $3.31–$3.35) still sits above the company's own $3.65B…

Beat-and-raise LTL margin story the tape only half pays for: after Q2 adjusted OR 79.9% and an at-least-200bps full-year guide, price lost the $199–$201 shelf on 2026-08-03 at $197.01 and reclaimed it 2026-08-07 at $202.58 with no company…

Q2 delivered into the 2026-08-04 FCC policy gap: revenue $191.9M (+86% YoY), first non-GAAP profit at $0.06 vs $0.01 consensus, capacity sold out through mid-2027. But the Q3 EPS guide of $0.11–$0.26 tops out under the $0.28 consensus,…

Order cadence is intact — 2026-06-17, 07-09, 08-04 — but the 2026-08-04 spike to $109.89 has bled to $103.07 (2026-08-07 close) with no company disclosure since. The second distinct hyperscaler AI-ASIC order that the $130–150M FY2027 guide…

Grid/advanced-conductor supplier to data-center and utility power; backlog still ~+40% YoY (~$280M), but the tape broke after the 2026-05-28 beat-and-soft-guide and a late-June Russell removal piled on passive selling. Below the lost ~$40…

BTC→AI landlord whose operating build (>1 GW contracted, ~$31B backlog, 175 MW live) has decoupled from an equity that halved from $49.65 to a $25.79 low, now bouncing off the $25.56 April base into a binary FY26 print on 2026-07-27.…

Reclaim leg running straight into the binary: 2026-08-03 +8% to $63.52 on Meta's WhatsApp-over-BlueBird workshop, 2026-08-04 +10.69% to $70.31 into the launch. BlueBirds 11-13 flew 2026-08-05; the 2026-08-10 Q2 call is the test — $14.7M…

Nuclear-uranium theme MATURING and CCJ's structure has broken twice into improving news: mkt cap $44.79B (06-29) → ~$39.9B (07-25), ~$88, ~35% off the $135.24 high, absorbing a $17.5B federal AP1000 program and NJ's $24B plan. Barclays cut…

Thune reversed on 2026-08-03 and put a pre-recess CLARITY floor vote back on the calendar, but no cloture petition had been filed as of 2026-08-04 and Polymarket prices 2026 enactment near 27%. The company-guided stablecoin markdown still…

Float-royalty leg is finished; the stock now trades on Arc. Q2 (2026-08-05) printed $73.3B USDC circulation and $701.3M revenue vs $718.6M consensus, but FY26 other-revenue guidance doubled to $310–330M and Arc mainnet targets 2026-09-16…

Four sessions took CRWV from the 2026-07-29 low of $60.55 to a 2026-08-04 close of $91.90 (+51.1%), stalling just under a declining 50-day $93.13 and 200-day $94.35 on Piper's $151 initiation and a 360 MW Indonesia build — while the credit…

Event contracts now out-earn crypto ($156M vs $100M in Q2) and private venue marks are re-rating — Polymarket in talks above $20B on 8/4 against Kalshi's $22B. HOOD closed higher twice off the $85.30 low to $93.51, but the 50-day $97.28…

Broken gov-capital quantum leg, now publicly capitulated: seven-plus down weeks, an inverse-ETF complex up to +108%, and Cramer warning it off air on 2026-07-23. Washed out but not based, heading into a binary Q2 print (est. 2026-08-05 to…

Neocloud re-rate has fully round-tripped: $33.62 close 7/17, -42% in 30 days, late-May Microsoft breakout base surrendered. Contracts intact ($9.7B MSFT, prepaid tranches) but Q3 AI revenue was only $17.3M vs a $3.4B ARR ambition, and…

Two legs now: contractual indium phosphide supply ($87M reserved to 2031-12-31, agreed 2026-07-29) and a draft FCC ban on new Chinese transceiver models (Reuters, 2026-08-04). AAOI's 2026-08-06 print and $255–290M Q3 guide confirmed cohort…

Capex-discipline leg died at the 2026-07-29 print; the replacement is Meta Compute — one hire, one call quote, still no signed customer. The two-session rebound to $587.94 (2026-08-04) stalled under the 50-day on lighter volume, and…

Preferred-peg repair funded by coin sales and common issuance is the live leg: MSTR closed $97.65 on 2026-08-04, a second gain after the 2026-08-03 disposal 8-K, while STRC sits at $92.53 against a $100 stated amount. The 2026-08-10 weekly…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78…

Three straight cohort-driven sessions carried OKLO from the 2026-07-29 close of $36.84 to $43.33 on 2026-08-04, with no Oklo release behind any of them. The 2026-08-07 Q2 call is the binary.

The $19.16–$19.83 shelf held eight sessions and PL gapped out of it on 8/4 to close $22.83, the highest since 7/21 — but both up days came on sector beta with no company news, on below-average volume. SpaceX's debut print beat on revenue…

Two unpriced agreements in six sessions — AT&T 07-27, Nasdaq Verafin 08-03 — carried QBTS back over the AT&T spike high on half the volume, but it still sits under a 50-day at $22.53. The 2026-08-06 pre-open print against a $4.03M…

Sector bid extended a second session on 2026-08-04 — QUBT $9.23, +26.4% from the 2026-07-29 close of $7.30 with no company news since 07-27 — but it was again the smallest gainer in its group and still sits under a $9.51 50-day line. The…

Quantum pure-play basket is in outright hype-cycle deflation: RGTI ~$14.19 (2026-07-17), -27% MoM, and the $14 shelf that held the May CHIPS-stake gap and the June executive-order pop has broken. Inverse quantum ETFs printing +108% and the…

Second up-day into tonight's print with nothing new disclosed: SMR closed $9.49 on 2026-08-04 (+5.33%), 25% above the 2026-07-29 base and still under a falling $9.90 50-day. Q2 consensus spans $1.0M (Zacks) to $8.80M (MarketBeat) on a…

Terafab (2026-08-06) put a number on the split: $16.8B first phase, and Musk's approximate guess allocates ~25% of output to Tesla Optimus versus ~75% to SpaceX — the listed entity co-funds compute it mostly does not receive. Energy is the…

Q2 (2026-08-05) missed both lines and rare earths contributed roughly $0.1M of $25.1M revenue, yet the tape made a higher low and closed 08-06 at $12.90, best since 07-14. The mine-to-magnet story now rests on the 2026-08-12 ASM scheme…

Peers raised 2026 guidance twice this week (TLN 08-05, CEG 08-06) and the complex still de-rated; VST fell 8.15% on 08-04 alongside NRG's -15.48% earnings break and closed 08-06 at $141.38, under the 07-29 flush low of $142.81. The 08-07…

Butterfly Embedded chip-licensing story got marquee validation — Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but…

Copper-to-optical interconnect narrative intact as a business (bookings into 2028, ~$1.9B NVDA stake) but the positioning trade is in distribution — ~35% off the 2026-06-02 ATH after correlated basket flushes. Week-of-7/21 semi rebound is…

Optical/AI-infrastructure demand is intact (Q1 Optical +36% YoY; Amazon/Meta/Nvidia deals) but the tape broke — a 43% drop off the 2026-06-30 ATH of $271.78 to ~$155. The 2026-07-28 Q2 print is the binary; two trading days out, nothing in…

Legacy crypto-financials name re-rating to AI-data-center landlord: Phase I ~200MW at the Helios campus was delivered to CoreWeave on 2026-07-06, turning the ~$4.5B/15-yr lease from promise into live contracted revenue while shares still…

Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)…

Post-liquidation base holding but not extending: four closes $99.81–$101.65 (2026-08-04 to 08-07) while volume decayed ~40% from the reversal day. Terafab's Grimes County site confirmation and SoftBank's $8.2B Intel gain add narrative…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 — a maturing,…

The WFE/AI-memory capex trade that ran Lam +119% YTD into June has rolled into a group-wide correction — the worst month for chip stocks since 2008, memory momentum broken (Micron/SanDisk). The ~2026-07-29 FQ4 print is now the binary: it…

US critical-minerals-independence trade keeps getting rejected: a bullish 2026-07-20 defense-sourcing executive order failed to lift MP, which fell 7.5% on 07-24 to a fresh 52-week low ~$41 (~58% off the Oct-2025 high). Best-case policy…

July de-rating unresolved and now compounded by capex scrutiny — Alphabet's first cash-flow-negative quarter since 2004 and Intel's punished $20B capex plan raise the question of whether hyperscaler spend slows. Jensen's open-weight-AI…

June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation — TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its…

The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly 0.78x the value of its 17.6M HYPE stack — a treasury premium that has flipped to a discount,…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

BTC-to-AI-landlord re-rating is structurally intact — AMD $311M/50MW Rockdale lease, $33.2M Q1 data-center revenue, Citi reiterated Buy/PT $28 on 2026-07-08 — but the miner complex rolled over on a Q2 crypto rout and "fresh AI-pivot…

Defense-backlog re-fire interrupts the mid-July rollover: the 7/20 $17B NSSL Phase 3 Lane 1 qualification and 7/21 $266M suborbital award stabilized the tape after the 7/13 support break and Piper's 7/16 Neutral $83 cap. An unresolved…

Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs — SPY003 IL-23 Part A (guided mid-2026,…

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)…

Q2 (7/16) beat every line and lifted FY26 growth guide above 40%, but the capex raise to $60–64B and a 2026-07-26 Samsung–Broadcom $200B foundry pact reopened the monopoly question. Theme cooled to maturing; price recovered to ~$415, still…

Conway extract/RTD/flavors platform inflecting capex-to-cash: Q1 (5/07) beat + record adj EBITDA + FCF-positive-H2 guide; the 6/30 debt-maturity extension cleared the refi wall. Stock re-rated to ~$9.50 near the $9.81 52-wk high. Q2…

Q2 (07-16) missed at $2.12 vs $2.25 and management cut the FY alumina outlook on Pinjarra refinery problems — five sell-side target cuts in nine sessions (BMO $55, JPM $52, WF $71), zero raises. The Hormuz premium is gone, the next…

BASX data-center cooling re-rating is intact but the setup for a fresh buyer today is poor: four days from a binary Q2 print (2026-07-30, inside blackout), KeyBanc just initiated at neutral (Sector Weight, 2026-07-23), ~55x forward with…

July's rotation-crown has slipped — Polymarket now gives Apple 20% odds of ending 2026 as the largest company (7/24) and semis are breaking out again (NVDA 7/23). The live narrative is the 'anti-CapEx AI trade' as Alphabet turns…

Second-leg breakout failed: after tagging a 52-week high $8.44 in early July, ABCL round-tripped to $5.31 (2026-07-24, -6.35%), losing the $6.79 shelf and $6.20 retest line, back at the June ~$5.09 base. The momentum edge is gone; what's…

CMS NTAP for ZEVASKYN granted 2026-08-04 plus a confirmed 2026-08-13 Q2 date have carried ABEO to within 0.7% of its $7.29 52-week high. The launch-ramp narrative is accelerating on reimbursement news, but the print is the binary:…

Single-asset UC biotech; the pivotal binary already fired (June 29 Phase 3 maintenance: ~50% Week-44 remission vs 10.4% placebo), the ~$920M raise cleared at $125, and 13 analysts caught it after the +36% gap. Now faded back to the…

Life-settlements franchise bolted the RWA-tokenization narrative (100+ policies on-chain, $224B TAM) onto a Q1 beat and a raised FY adj-EPS guide, but shares rejected the $12.44 high with a −7.3% sell-the-news day into a binary ~2026-08-06…

US-reschedule sentiment is spent for this name: the DEA Schedule-III hearing closed July 15 2026 with no ALJ timeline, and the economics accrue to US operators, not a Canadian LP. The Aug 5 Q1 FY2027 print is a guided transitional-year…

Oil-shock beta has decoupled: the Strait of Hormuz is physically shut yet WTI holds ~$71 on a rebuilt glut, while ProFrac sits in its 52-week-low neighborhood (last ~$4.90, 2026-07-09) over a loss-making frac core and ~$1.05B net debt. The…

June memory/HBM semicap re-rating that ran ACLS to a $193.78 high has broken; stock chopping ~$134 (−5.2% on 2026-07-24), ~31% off high, on flat FY2026 revenue. Forward path is now two binaries: the 2026-08-06 Q2 print and the…

Post-crash re-rating leg: the 2026-06-18 FY26 guide cut took ACN -17.9% in a day to a $118.15 low, then a $7.5B buyback (+62% YoY, must complete by 2026-08-31) plus named AI wins (Google Cloud, NATO, UniCredit) drove +24.8% in four…

Record-revenue franchise priced for terminal AI disruption: closed 2026-07-31 at $250.41, ~9.6x NTM earnings vs Microsoft 23.1x, 31% below the 52-week high, with a $25B buyback running. The bear narrative is fully mainstream and nothing…

Analog cyclical-trough plus the $1.5B Empower AI-power option fired and fully repriced in one week around the ~2026-05-20 Q2 print; ten weeks on, four more target raises (Cantor $550, Keybanc $525) are sell-side catch-up on a told story…

De-rated design-software compounder: Q1 FY27 revenue +18% to $1.934B and current RPO +18%, against a stock 23.8% under its $326.79 high. The $3.6B MaintainX close (2026-08-03) extends the franchise from CAD seats into asset operations; the…

The ADVA-merger margin-recovery turnaround — the whole reason for the ~$7→$20 re-rate — cracked on the 2026-07-22 preliminary Q2 miss (rev $280–282M below guide, non-GAAP operating margin ~3.5–4% vs a 5–9% target, GAAP loss, EPS collapsing…

Datacenter-power picks-and-shovels re-rating is now fully mainstream — Morgan Stanley initiated Overweight $421 (07-22) atop Wells $465 and Susquehanna $535 — yet the stock fell 12.65% on 07-02 and is sitting on its 200-day while analyst…

Frac-sand legacy pivoting to behind-the-meter gas power for AI data centers, but the story is DORMANT and the structure broken: shares fell from $16.73 (6/29) to an $11.96 close (7/24, -8.5%), losing the ~$15 base and $13 shelf on…

The +80%-off-March recovery re-rate has matured and rolled over: Morgan Stanley pulled its Overweight ('valuation call') on 2026-06-25, and price faded ~30% from the $100 high back onto the reclaimed 200-day near $70 while targets stayed…

AI-data-center gas-EPC theme still ACCELERATING (4.1+ GW gas backlog, $973.6M cash, zero debt), but AGX has round-tripped from the $805.75 ATH to $563, losing both the ~$675 breakout and ~$600 shelves. Mean reversion toward the pre-run…

Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that…

Semiconductor-IP royalty re-accel (Q1 variable royalties +67% YoY, FY26 guide raised to $91-95M) is fundamentally intact, but a $48.59 blowoff top (6/30) reversed ~29% and closed back below the ~$39 breakout shelf. Momentum leg is broken;…

AI-agent-security theme is accelerating, but AKAM's July 8 re-firing (+8–10% toward $126) has fully faded to ~$115, rolling back toward the June lows — a legacy-CDN-to-security/compute pivot that is NOT confirming the theme's momentum. The…

VOICE outcomes win (USRC trial stopped early, June 2026) de-risked Vafseo's dialysis-anemia case, but the tape bled to ~$1.22, only ~48% above the $0.82 low and still fading; the late-July/early-August Q2 print is the binary —…

Coverage-and-flow leg has crested: -25% from the 2026-06-30 all-time closing high of $32.23 to $24.13 on 2026-08-07, no new sell-side action since JPM's 2026-07-14 maintain at $33, and three insiders selling in July's post-lock-up window.…

AI rack-connectivity leader caught in a cohort-wide de-rate: down ~42% from the late-June $499 ATH as semis log their worst month versus software and the "is the AI trade cracking" question takes over. The $300 June recovery base is gone,…

The June AI data-center power-attach re-rate has flipped from being marked up to marked down: TD Cowen cut its target to $66 (2026-07-13) and Barclays downgraded to Equal-Weight at $48 (2026-07-20), the first target below the June range —…

Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares…

June fuel-relief momentum trade failed at its 2026-07-21 binary: Q2 economic fuel spiked 85% YoY to $4.43/gal (no Hormuz relief), revenue missed at $4.065B, and Q3 guided to $0.00–$1.00 adj EPS vs $1.38 est. Sell-side now cutting targets…

Door-hardware compounder gapped +12.6% on 2026-07-23 after a Q2 beat (adj EPS $2.40 vs $2.22) and an FY26 guide raise to $8.85–9.00; durable legs are the electronic-access mix shift and an emerging data-center physical-security vertical…

Best-in-class oral TYK2 story sitting near 52-week highs (~$28) as the market waits on the Q3 2026 LUMUS Phase 2b lupus topline — the binary that either re-rates envudeucitinib into a multi-billion indication or caps it as a psoriasis-only…

Closed special situation: Arcline's $29.00 all-cash take-private (signed 2026-06-16, ~$272M, Q3-2026 close) hard-caps the stock. At $28.65 (2026-07-21) only a ~1.2% arb spread remains after the 2026-07-16 preliminary proxy — a frozen…

Ethanol-to-specialty/low-carbon pivot re-rated ~6x off $0.92, but both fuel catalysts — the June 45Z cash sale and the Russell index add — are spent, and price has round-tripped from the $6.11 July high to ~$4.64, losing the $5.10-$5.20…

WFE toll-collector on the AI-silicon buildout. June's +54% parabola — the most overbought reading in its history — corrected in July's semiconductor selloff that validated Burry's short. Now a pullback-to-base test: the June breakout base…

Edge-AI silicon small-cap re-rating on Roth Capital's 2026-07-14 Buy initiation at a Street-high $125 PT, which re-opens upside above the spent $70 Needham/UBS cluster. But the last confirmed tape is the 2026-06-05 -12% distribution day,…

A second anchor — the $1.5B Nvidia advanced-packaging/test partnership (2026-07-23) stacked on the 2026-06-16 TSMC 10-yr Arizona deal — is re-rating Amkor from single-customer Apple OSAT toward US AI back-end anchor. But every catalyst…

Single-asset binary: Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia is guided for late August/early September 2026 (reaffirmed 2026-08-06), while the stock has run 54.9% in three months to within 5.7% of its 52-week…

Healthcare-staffing cyclical recovery, real but MATURING and now at the highs: ~$32.9 (2026-07-24), just off a fresh 52-wk high $36.27 (~+120% off $14.87). Truist's 2026-07-22 lift to a Street-high $40 Buy is the first target leading…

AWS +28% YoY (Q1, a 15-quarter high) keeps firming while the 2026-07-30 Q2 print lands days after Alphabet's best-ever quarter shed $294B on capex fear. Fundamentals accelerating, hyperscaler-capex sentiment rolling over — the print is the…

The July 14–17 Delaware bench trial closed with no verdict and no buyout; the quick-resolution crowd unwound and ANAB round-tripped from the low-$70s to ~$54 (Jul 24). The whole equity is now a dateless wait on a Chancery post-trial…

Professional-services roll-up re-rating: from a $16.00 IPO on 2025-12-17 to a $47.33 close on 2026-07-31, powered by the 2026-05-12 guidance raise to $980M–$1.0B FY2026 revenue. Price is discovered on a 10.90M-share float with a fifth to a…

Precision-psychiatry re-rate (~10x off $2.85) re-armed on 2026-07-13 — a successful FDA meeting cleared an additional ALTO-207 monotherapy Phase 3 in TRD, funded same-day by a $100M raise at $26.48. Narrative refreshed, but every data…

Post-parabola digestion. The Apr–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully priced, above the $30.50 consensus PT with no fresh company catalyst in 11+ weeks; the 2026-07-15 pop was a newsletter-driven volume spike,…

AbbVie's signed all-cash takeout at $135.11 (announced 2026-06-23, ~$10.9B, ~49% premium to the $90.38 pre-bid close) caps the stock at the bid and killed the IL-13 momentum leg. What trades now is merger-arb carry into an expected H2-2026…

Bitcoin-treasury premium stays inverted: the July 20 buy was just 21 BTC at $63,221 (19,921 coins), accumulation has slowed to a trickle while mNAV sits at a discount and the $2.55B ATM dilutes BTC-per-share. TD Cowen's July 22 target cut…

Advanced-packaging pricing power is real — quotes raised 20%+ (2026-07-01), 2026 capex hiked to US$8.5B, CoWoS-equivalent capacity tripling to 25k wpm — but the tape topped at $45.51 the same day and sits ~15% lower inside a 13% semi…

Rumor confirmed and cashed: Eli Lilly is acquiring AtaiBeckley (announced 2026-07-16) for $6.75/share cash plus up to $2.50 CVR tied to BPL-003/VLS-01 milestones. Shares gapped to ~$7.20 and desks cut to Hold en masse — momentum is dead,…

AI-security re-rate off the 2026-06-15 TrojAI deal has stalled: ATEN churning ~$35 below the $37.36 ATH, momentum cooling as Mizuho lifts its target to $34 but stays Neutral — analyst catch-up, not fresh conviction. The 2026-08-05 Q2 print…

AI test-intensity picks-and-shovels leader, but the narrative is MATURING: back-to-back upstream capex raises (TSMC $60–64B, ASML €43–45B) failed to lift the tape, and the ADR sits ~20% off its 2026-06-25 record, shedding another 6% on…

Cash-return re-rating in a shrinking business: EV of US$27m against US$2.67bn cash, a US$400m buyback authorised 2026-07-28 (~15% of market cap) and a restated RMB1.5bn 2026 dividend floor drove a +40% run off the 2026-06-05 low of $16.53.…

Cyclical-bottom bounce off the $69.69 200-day (7/16 low $68.95) has firmed price into the low-mid $70s, but ATKR sits below its $78 50-day with the Street uniformly at Hold (0 Buy/3 Hold/0 Sell) into a binary 2026-08-04 Q3 print. A base…

Gold/copper producer basing $53–$76 under a broken ~$72 shelf after a ~45% fall from the $110 high. Q2 output slipped 8% QoQ — first sequential drop after a record Q1 — as gold cools to the low-$4,000s and sell-side keeps trimming (JPM to…

Aurora shipped its scale-readiness milestone — second-gen International LT trucks with the safety driver removed (2026-07-22) — and the tape sold it, breaking the ~$6.00 base to ~$5.83 into a confirmed 2026-07-29 Q2 print. Good news, no…

Take-private is done: AVNS holders approved the $25.00/share all-cash AIP buyout on 2026-07-22 (~99.75% of votes cast), all regulatory clearances in hand, close guided by 2026-07-27 with NYSE delisting on completion. Price is pinned to…

TAVR disruptor whose de-risking catalysts (CMS CED, first US patients, French ANSM clearance) are now exhausted; price faded ~11% off the ~$11.06 high back onto the in-the-money $250M ATM near $9. No 30-day data binary — PARADIGM readout…

Self-help turnaround at a leveraged lab-supply distributor is being repriced: the 2026-07-29 Q2 print put VWR Distribution & Services back to +1.7% organic from -4.8% in Q1, and FY2026 organic guidance was raised to -0.5%/+0.5%. Price…

Beat-and-raise fired 2026-07-08 — Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum — but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells…

Parent-level distress in the courts: ~2026-06-26 60-day São Paulo shield plus Chapter 15 in SDNY, Fitch C / S&P default (2026-06-30); management skipping ~$177M July–Aug coupons and pushing an extrajudicial plan (5-yr extension, 100% PIK)…

Late-stage small-cap CPaaS squeeze: +360% YoY into the mid-$70s, ~5% below the $79.08 high, with Citizens ($86, 2026-07-20). Riley ($85) both lifting targets in July. A confirmed Q2 print on 2026-07-29 is a binary two trading days out —…

Q1 FY27 gave the pivot real numbers (QNX $72.3M vs the $60-64M guide, FY27 raised to $594-621M), but the parabola broke: after a $13.59 high the stock fell ~37% to ~$8.54 on a meme unwind plus insider selling. Narrative maturing, price…

Lemonis "Everything Home" roll-up keeps closing deals — Container Store now wholly owned (2026-07-08), TwoPonds folded in (2026-07-01) — but the tape has bled from $5.83 to ~$4.96 and sits on the $4.26 52-week low as shares balloon past…

Broken-growth AID-pump name idling into a binary Q2 print (~2026-07-28, ~2 days out): the number decides whether new patient starts re-accelerate or post a second straight sequential decline. Two clustered sell-side PT raises (Goldman $19,…

Rotation-passenger thesis is dead and the self-help turnaround hasn't ignited: BBWI made fresh relative lows near $19 into the 2026-07-12 Ulta launch, down ~42% over 12 months and below its 200-DMA while the tape holds up. Goldman cut to…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,…

On-site SOFC power for AI datacenters stays ACCELERATING and cluster-confirmed — Oaktree/IDF's $1.7B project financing (7/16) blunts the July supply-wall short thesis and JPM lifted its target to $346 (7/21) — but the ~2026-07-30 Q2 print…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 — the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M…

De-rate reversal off the $7.48 Nov-CRL low has stalled near $14 after peaking ~$16 in early July; the opakalim epilepsy pivotal (RISE3) topline is unscheduled 2H-26, sell-side is turning cautious (BofA Underperform $11), and a dilution…

De-risking headlines (dual-primary HK listing approval, Apple Intelligence China clearance, mid-July) rallied the HK lines but the ADR kept bleeding — cap down to $37.21B (07-24) from mid-$40B in June. Structure rolled over below the $110…

Statin-for-inflammation leg broke on someone else's Phase 3: Novo's ZEUS missed MACE at HR 0.99 on 2026-07-31 despite lowering hsCRP, and BIOA fell 59.6% intraday. QUELL-CV's primary endpoint is hsCRP — the exact surrogate ZEUS just…

Post-miss +46% V-recovery has rolled over — ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Post-Q2 re-rate on capital return: the 2026-08-04 print delivered adjusted EPS $2.54 (+15%) on revenue +8%, $3.7B repurchased and a raised $650M savings target, and ten firms lifted targets on 2026-08-05. But room nights are guided to…

The +80% Q1 turnaround re-rate round-tripped from the $6.57 high and stays broken: BLDP trades below the lost 20-EMA (~$5.00) and the $4.80 shelf in a catalyst vacuum until the 2026-08-12 Q2 print, with Susquehanna's 2026-07-10 cut to…

Busted vertical-SaaS name re-rating on cash return: the 2026-07-29 Q2 print showed +3.0% organic and an affirmed FY26 guide with upper-half commentary, against ~$850M of remaining buyback authorization and an 8.16 forward P/E. The move is…

Casual-dining margin-repair story re-rated violently on the 2026-08-05 Q2 print (adj EPS $0.39 vs $0.29, FY26 adj EPS guide lifted to $0.90–$1.00). The narrative is three days old and already gave back from $12.29 intraday to a $10.95…

Argentina disinflation/credit-recovery basket; BMA is the best-capitalized domestic vehicle. Sequential CPI is genuinely improving (3.4%→2.6%→2.1%→1.9% MoM, Mar–Jun 2026), but the tape has gone nowhere since the Oct-2025 midterm leg — ~$90…

The premium-to-NAV engine that funded BitMine's ETH ramp has closed: $11.35B market cap on the 2026-08-07 close against $11.3B of stated holdings on 2026-08-02. What is left is an ETH proxy at book with a $4B buyback (16.1M shares retired…

Still a merger-arb wrapper rather than an oncology stock: the object is a planned $44–48M pre-close cash dividend plus a 3.69% stub in the AATD base-editing NewCo. The 2026-08-07 10-Q re-documented it ($72.6M cash, 75% RIF), but price has…

The 2026-08-04 Q3 print resolved the binary against the margin case: adjusted EBITDA margin 13.7% vs the ~16% guide, and FY26 EBITDA cut to $275–295M from $315–335M even as the sales guide rose. Demand held, profitability did not. Price…

Post-ASMS instrument re-rate broke back toward the $64.54 high and added a second leg: semiconductor-metrology strength (orders +20% YoY) pulled Leerink to $70 and top targets to $65–70. But at ~$62 the name sits ~13% over its 50-DMA and…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up — Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Legacy oiler U.S. Energy rebranded June 8 2026 into Big Sky Industrial, a helium + carbon-capture pivot at Montana's Kevin Dome. A five-year $285/MCF take-or-pay offtake and Q1-2026 FID anchor the story, but first cash flow is Q1 2027 and…

Both legs of the wrapper are now rolling over: WhiteFiber (WYFI, ~70.5% owned) de-rated from $38.50 to $27.57 as the June neocloud mania cooled, and BTBT slid to ~$1.50, a step above its $1.25 low. SOTP discount still ~49% (~$745.6M WYFI…

Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the…

July's Hormuz flare re-armed the oil-geopolitical premium, but it has since drained — WTI slipped to the low $70s and the 2026-07-17 sanctions wind-down passed with no barrel shortage, a contained-conflict bid rather than a supply shock.…

Broken IPO that cleared its 2026-07-21 lockup without a supply flood but is grinding on the $4.665 all-time low with no bounce; Goldman cut its target to $7.75, and the undated $100M Galaxy verdict plus the ~2026-08-26 Q2 print are the…

Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,…

Housing-distribution margin inflection in a 7.86M-share float: the 2026-07-13 Trex distribution award plus a 2026-08-04 Q2 beat (adj EPS $1.15 vs $0.40 est) carried BXC to a 52wk high at the 2026-08-07 close of $89.88 — above both targets…

CAN-2409 lung program promoted to pivotal on the 2026-06-30 AURORA Phase 3 launch, and sell-side keeps stacking (Stifel Buy $22 on 7/13, avg PT ~$20 vs high-single-digit spot) — but the June breakout to $11.36 round-tripped to ~$9.50 and…

Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the…

Q1 re-rate is spent and the tape has gone flat — CAL has chopped a tight $11–$12.6 band near $11.78 (2026-07-24), ~19% below its pre-print level and under the lost low-$13s June shelf. Slow brand-mix-shift value name, not an accelerating…

Legacy-diner turnaround has handed off from numbers to leadership: David Deno (ex-Bloomin' Brands CEO) takes over 2026-08-10 with shares roughly doubled YTD and the 2026-08-07 close of $57.79 above every published target except Argus's…

Activist-driven re-rate on a cheap professional-services roll-up: Reference Equity's July 7 letter to halt buybacks and resume M&A drove a +9.3% pop, and the tape is +36% in 30 days straight into a July 29 earnings binary that confirms or…

Cash merger-arb in its final mechanical innings: shareholders adopted the $13.25 Knox Lane take-private on 2026-07-16 (~72% of shares for) and HSR is cleared, leaving only customary closing before delisting. Pennies of upside vs a residual…

Humanoid-robotics de-SPAC: Churchill XI merges with Agility Robotics (~$2.5B, Nvidia/Amazon-backed, re-lists as AGLT). Theme intact, but the tape is an RSI-98 filing-driven blow-off that has since gone quiet with no dated catalyst until…

Post-blowoff digestion is deepening: the ~4x data-center site-work roll-up has bled from a $96 high back to its $63 average analyst target, now below the $73 secondary price and the 50-DMA. Q1 organic +64% and an $854M backlog keep…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

2nd-order AI-power name — Q1 orders +97% YoY and a first-ever >$1B backlog (2026-04-28) feed the datacenter/electrification capex wave, and the closed Thermon merger doubled EBITDA. But price rolled over ~25% off the $101.24 ATH to $75.63,…

Analyst-confirmed profitability inflection (Q1'26 adj-EBITDA +$4.0M, +24% product rev) in a 25-year blood-safety grinder, but the 2.7x off the lows is largely spent and price sits near 52-week highs (~$3.00). The 2026-07-30 Q2 print is now…

Edge-AI IP momentum leg has broken: June's reclaim to within ~3% of the $51.60 high failed, and the mid-July AI-capex scare (Moonshot model) drove shares back through the ~$44 base to the mid-$30s. Sell-side still carries $48–$55 targets,…

The rescheduling binary CGC trades on came and went: the DEA hearing closed 2026-07-15 with no verdict, briefs due 2026-08-17 and the ALJ recommendation undated into H2 2026, likely litigated into 2027. Shares closed $0.89 on 2026-07-24,…

Busted-IPO fintech: operations accelerating (Q1 rev +25% to $647M, first GAAP profit, FY guide raised to $2.66–2.69B) but the stock trades ~19% below its $27 IPO and bases near post-IPO lows — a compressed multiple, not an accelerating…

The 1.6T WaveLogic demand cycle is intact at the order book, but the trade has broken: $627.00 (06-02) to ~$370 (07-18) is a ~41% de-rating, and the $455–$467 shelf that framed the prior read is gone. Multiple compression from 54x forward,…

The May earnings-miss squeeze has fully round-tripped to a dead tape in the mid-$30s, below the ~$36 gap base, with the retail-sentiment narrative spent. The sole live driver is the 2026-08-05 fiscal-Q3 print — guided to a sharp sequential…

Court-ordered 4.5-Star legal win (2026-06-10, +18.9%) is a spent binary; the $4.23 breakout is holding near $4.32 as Canaccord lifts its target to $5.50 (2026-07-21), but the confirmed August 5 Q2 print — carrying the promised FY guidance…

Picks-and-shovels delivery play on CNS gene therapy: ClearPoint's SmartFlow cannula and MRI navigation are the standard route to the brain for uniQure's AMT-130 Huntington's BLA (soft Q3-2026 window). The June re-rate held near $18.72…

AI-datacenter EMS picks-and-shovels story still fundamentally climbing after the 2026-04-27 Q1 crush (rev +53% to $4.05B, FY26 guide raised to $19B), but the tape broke ~21% off its $474 June high and heads into a binary 2026-07-27 Q2…

Pure-play SBS paperboard cycle inflection: two announced $60/ton price increases plus ~300kt of industry capacity out YTD took Q3 adjusted EBITDA guidance to $20–30M from negative $8M in Q2. But the 2026-08-07 close of $23.31 is a 52-week…

Hormuz war-risk re-escalation fired — the US-Iran MoU collapsed and tankers were struck 2026-07-19/20 — yet CMBT stalled near $15.7, ~11% under its $17.72 high, while broad VLCC spot bled ~40% off the late-June ~$470k/day peak. The equity…

Sell-side cluster finally formed — Citi Buy/$45 and Mizuho Outperform raised to $41 (both 2026-07-13) joining JPM's Overweight, plus first Mexico restaurant announced — but the ~2026-07-22 Q2 print is three days out and no weekly 20-EMA…

Takeover optionality cleared its first test: the 2026-07-29 Q2 beat (adj EPS $1.38 vs $1.11 est, organic +6%) and raised FY guide ($4.48–$4.60) removed the standalone-collapse case and carried price to $49.12, above every dated sell-side…

Terminal special situation, unchanged: Lilly's $38.00 cash plus up-to-$9.00 non-transferable CVR scheme became effective 2026-06-24, last Nasdaq print was 2026-06-23, and Form 15-12G is dated 2026-07-06. The only live development is…

Q2 FY26 (2026-07-23) beat on every line — net sales $216.2M +28.1%, EPS $0.82 vs ~$0.55, FY guide raised to $790–805M — and the stock still closed $62.25 on 2026-08-07, -25.9% from the post-print high. Beat-and-raise absorbed by sellers;…

Fee-reform catalyst landed: the 2026-07-13 Ninth Amended MSA cuts the base fee from 2.00% to 1.25% of ANA and caps 2027 base fees at $30M (est. $19–22M saving) — but nothing hits P&L before 2027-01-01. Price recovered ~$10.08 (2026-07-08)…

Now stretched into a binary ~2026-07-29 Q2 print ($4.0–4.2B guide) with an open NY AG antitrust probe.

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

Distressed, highly-levered beauty turnaround (net debt ~$3.17B, ~3.3-3.4x) bouncing +23% off its ~$1.82 all-time low on the ~$400M Gucci license transition to Kering and cost-out. A de-lever story, but the ~Aug-19 Q4 print is the binary…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Hardware-to-platform crossover: Q2 2026 Platform revenue $85.0M (+5%) now exceeds Products $71.3M (-22%), and shares gapped +22.9% on 2026-08-05. The fuel was non-recurring — $20.3M IEEPA tariff refunds plus a $6.4M reserve release; the…

Elliott-driven turnaround at a beaten-down CRO: a ~$295M cost program plus 120–150bps margin expansion is re-rating the stock even with organic revenue still negative (-1.5% Q1), while Q1 proposals up high-single-digits YoY hint DSA…

Momentum leg is dead: the story crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to ~$83.50 and now trade as a merger-arb spread capped at $85 with ~$40 of air below on a break. Residual…

Turnaround re-rating still catching fresh fuel: analyst targets cluster up to $160 (BofA 2026-07-23, Seaport 2026-07-20) on North America DTC re-inflecting, lifting CROX to ~$135 within 4% of its all-time high at ~10x forward. Revenue is…

Aero-defense superalloy pricing cycle intact (three contracts at >30% hikes; Q4 op-income guide $205-210M, +37% YoY), but the July flush to $532 has been bought back to ~$603 straight into the 2026-07-30 Q4 print — now four sessions out…

Margin-inflection leg: Q2 FY26 (2026-08-06) delivered adj EPS $0.23 vs $0.07 consensus, a record 33.2% gross margin and an FY26 EPS guide of $0.85–$0.94 vs $0.72 est. Price closed 2026-08-07 at $14.35, the 52-week high and above three of…

Takeover-premium leg is dead: the 2026-07-06 Vista/Quinti gap is fully filled and the 2026-08-05 print cut FY26 contribution ex-TAC guidance to $1.034–1.058B from $1.175–1.198B, re-basing the standalone any bid would price. No board…

The 2026-08-06 Q2 update pushed the registrational PTCL interim from late 2026 to a Q1 2027 futility analysis that publishes no efficacy data, and set AD Phase 2 topline at Q3 2027 — the binary clock this name traded on is now empty until…

Legacy-networker AI re-rate intact and now at its binary: the $118–120 shelf held through July, price closed $121.43 on 2026-08-07 with RSI(14) at 78.4, and five sell-side target raises landed 07-22 → 08-06 (Citi $112→$139) ahead of the Q4…

Policy-relief leg stayed dead: the 2026-07-24 Jeffersonville HJT cell-plant opening — the reshoring narrative's first hard proof point — drew no bid, with the 2026-08-07 close at $15.91, 52.6% under the $33.58 adjusted high. The 2026-08-27…

Value-apparel turnaround is fundamentally accelerating — Q1 FY2026 comps +13.9%, a 21-month positive streak, a raised FY guide — but the 2026-06-02 print was the catalyst and it fired ~7-8 weeks ago. On an ~8.1M float with 10.5% short…

Legacy IT-services name being re-underwritten as an enterprise-AI deployment partner: 2026-07-29 Q2 lifted FY26 adj EPS guidance to $5.70–$5.82 and expanded margin 40bps while cutting the FY revenue band to $22.04–$22.35B. The re-rating is…

Post-exemption refining recovery is measurable — Q2 2026 adjusted EBITDA $209M vs $99M a year ago, refining margin $9.94/bbl vs $2.21 — but the tape has stopped paying: $31.15 close on 2026-08-07 is 21.9% under the $39.89 high, and…

The margin-inflection leg broke at its own catalyst: Q2 (2026-07-29) adjusted OR 95.9% vs 94.6% PY — second straight quarter of YoY deterioration — revenue $332.9M missed $340.4M, and Stephens cut its 23-day-old target to $54 on 07-31.…

Currency/payments spinoff re-rating on two legs: a US "Catalyst Series" banknote redesign (redesigned $10 late 2026, higher-denom print volume ~+90% vs 2025) plus a De La Rue + Antares authentication roll-up (SAT sales +51% YoY, FY sales…

June's $50M raise at $3.05 (16.4M sh) is already underwater: shares last $2.775 (2026-07-02), below the offering floor, with ~$50M shelf undrawn and soft Q2 guidance (rev $93–95M, adj. EBITDA still negative) into the 2026-08-10 print. A…

June's sell-side upgrade wave has exhausted and the first cut printed — Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the…

Definium re-accelerated off the June Phase 3 MDD win: a Wells Fargo initiation at $68 (7/27) and Piper's $75 (8/7) carried it to $46.14, 4.8% under the 52wk high. The leg being bought is DT120 as a multi-indication CNS franchise — and the…

The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through…

Fusion pivot is the leg: the 2025-12-18 all-stock TAE Technologies merger (>$6B, ~50/50 fully diluted) is what's actually being bought, while the crypto-treasury leg was terminated 2026-08-07. The S-4 was still unfiled as of 2026-08-05,…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

Fundamentals accelerated on the 2026-08-04 Q2 print (revenue +29% YoY, AI ARR +212%, RPO $894M, FY guide raised) and the stock fell 10.9% anyway. The $132 shelf flagged in the July coverage broke; the 2026-08-07 close is $124.15, -31.5%…

Legacy e-signature base being re-wrapped as AI "Intelligent Agreement Management" — IAM went 10.8%→12.6% of ARR in one quarter and is guided to ~18% by 2027-01-31, but total growth is still ~9%. Price has recovered to roughly the consensus…

The June–July re-rate has run into an empty calendar. The 2026-08-03 Q2 update pushed DT-168 FECD data to 2027 and re-cut RESTORE-FA to a 10-patient 12-week cohort with blood FXN protein as the primary efficacy endpoint, moving the next…

The pivot is now structural: the rail subsidiary was sold 2026-08-05 (related party — interim CFO owns 50% of the buyer), leaving an edge-colocation operator carrying a 2026-07-16 five-year 10 MW hyperscaler contract worth >$111M. The tape…

Census-recovery re-rate broke at the 2026-08-04 Q2 print: EPS beat ($4.02 vs $3.88) but FY26 EPS was only affirmed at a $14.65 midpoint vs $14.82 consensus, with H2 revenue-per-treatment guided slightly negative. Price -23.7% from the…

Legacy IT-services decliner being re-rated as an AI-centric pivot: AI-framed leadership change 2026-07-30, ElevenLabs and Primary partnerships inside ten days, FY27 non-GAAP EPS guide of $2.40–$2.90 affirmed against a $10.84 close.…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is…

Scarcity-premium narrative is dead: DXYZ closed $22.51 on 2026-07-28, below its last reported $24.56 NAV (2026-03-31), then bounced to $25.89 on 2026-08-07 as SPCX absorbed its 911.5M-share 2026-08-06 unlock. What trades now is a near-NAV…

Legacy IT-services base re-rating on an AI-delivery pivot: the 2026-07-29 Q2 beat (adj EPS $0.91 vs $0.82) plus a $115M Army DEVCOM AI award drove +16.3% on 2026-07-30. Revenue is still -1.3% YoY, RSI(14) hit 94.5 at the 2026-08-07 close…

June 11 was the last new clinical datapoint; what carried price to $60.46 on 2026-08-07 was the 8/5 Q2 print ($895.2M cash, runway into 2030, Fast Track) plus a same-week target cluster (Stifel $82, GS $80, Guggenheim cut to $78). Funded…

Lithium-recovery narrative is broken: Q4 FY26 revenue US$31M (−61% QoQ) at a realized US$921/dmt as legacy pricing rolled off, and Guangzhou carbonate hit a five-month low CNY 136,800/t on 2026-07-22. The new fact is a divergence — the ADR…

Post-collapse deleveraging read: Q3 FY26 (2026-08-07) beat at $271.7M revenue and $0.56 adj EPS vs $0.27, and the FY26 adj EPS guide went to $1.80–$1.90 — three months after a 57.8% one-day break on 2026-05-05. The leg being bought is a…

Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the self-help story, but price has rolled over from $34 toward $27 while three brokers cut targets.…

IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled — stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST…

AI-native revenue is compounding ($160M in Q2, >11% of total) but the task-based book is running off faster — FY26 organic constant-currency growth was cut to 2.0%–3.0% on 2026-08-06, Q3 guided to ~1.7% YoY, and the stock closed $97.43,…

Take-private special situation: the board rejected Yellow Wood's $30 bid as too low, and mid-July sell-side PT raises (Canaccord $34, Wells Fargo $30) confirm a >$30 intrinsic read. But a month on no competing bid has surfaced, the theme…

European winter gas-security theme re-accelerating; Equinor, the swing Norwegian pipeline supplier, held ~$40 through a Q2 double-miss on a $1.125B buyback bid. But at ~$40.31 (2026-07-24) it trades above the entire sell-side PT range (avg…

Post-crash story reset: 2026-07-13 updated ERAS-0015 Phase 1 data (57% uORR at 32 mg in 2L+ KRAS G12X pancreatic, n=7) plus 2027 pivotal plans, immediately monetised via a 31,428,572-share offering at $17.50 on 2026-07-14. Funded, but the…

Resolved and off the tape: ARCHIMED closed its take-private of Esperion on 2026-07-13 at $3.16 cash plus a non-tradeable CVR of up to $100M aggregate, and the common stock ceased trading and delisted the same day. Last listed close was…

Smadex AI-DSP re-rate broke to a new 52-week high of $13.48 with no dated company news since 2026-07-12 — an anticipatory leg into the 2026-08-10 Q2 print, the binary on whether Q1's +204% ATS growth and ~22% EBIT margin held.…

The late-June retail bounce has fully unwound — EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which…

Legacy expense-SaaS pivot re-rated on the 2026-08-06 Q2 print: revenue $33.9M beat $33.688M, paid-member decline halved to -2% YoY, FY26 FCF guide doubled to $12M-$14M, ~7% of shares retired, and New Expensify ARR from net-new customers…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania — down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217%…

Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays…

Street targets re-rated up to the price rather than the reverse: average PT $22.83 across 8 analysts vs the 2026-08-07 close of $20.43, after B. Riley $13→$32 (6/29) and UBS $22→$27 (7/14). The AI-power bid still works (7/30 Microsoft…

Design incumbent re-rated as an AI winner (BofA Buy, $30 PT, 7/7) rather than an AI casualty, yet the stock churns below its 100/200-day moving averages with heavy short interest into its first public earnings print on 8/5 — that print,…

Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26…

AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1…

Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the…